Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
CALCITRIOL vs CALDEROL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.
Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.
Management of hypocalcemia in patients undergoing chronic renal dialysis,Secondary hyperparathyroidism in patients with chronic kidney disease not yet on dialysis,Hypoparathyroidism (post-surgical, idiopathic, or pseudohypoparathyroidism),Off-label: Vitamin D-dependent rickets type I and II, osteoporosis (as an adjunct)
Osteoporosis,Vitamin D deficiency,Renal osteodystrophy,Hypoparathyroidism
0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.
Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.
5–8 hours (terminal) in normal renal function; prolonged up to 18–24 hours in chronic kidney disease (CKD) due to reduced clearance.
Terminal elimination half-life is approximately 20-30 hours; clinically, steady-state is achieved within 5-7 days.
Primarily metabolized in the kidney and intestine via 24-hydroxylase (CYP24A1) to inactive metabolites (e.g., calcitroic acid). No major hepatic cytochrome P450 involvement.
Hydroxylated in liver to 25-hydroxyvitamin D; further hydroxylated in kidney to active 1,25-dihydroxyvitamin D.
Renal (fecal after biliary excretion of metabolites): ~10% unchanged in urine; ~70% as metabolites in feces via bile.
Primarily fecal (biliary) as unchanged drug and metabolites (approx. 80%); renal excretion accounts for less than 20%.
~99% bound to vitamin D-binding protein (DBP) and albumin.
Approximately 99% bound to serum proteins, primarily to vitamin D-binding protein (DBP) and albumin.
0.5–1.0 L/kg (indicates extensive tissue distribution, primarily to kidney, intestine, bone).
Vd is approximately 0.4 L/kg; reflects distribution into total body water with negligible storage in fat.
Oral: ~70% (rapidly absorbed from small intestine). Intravenous: 100%.
Oral bioavailability of calcitriol is approximately 70-90%.
GFR 15-59 m L/min: initial dose 0.25 mcg orally once daily; GFR <15 m L/min: avoid use or use with caution, dose adjustment not established.
e GFR <30 m L/min/1.73m2: reduce dose by 50% and monitor calcium/phosphate levels; e GFR <15 m L/min/1.73m2: avoid use due to risk of hypercalcemia.
No specific guidelines for Child-Pugh; use with caution in severe hepatic impairment as calcitriol metabolism may be altered.
Child-Pugh class B or C: reduce initial dose by 50% and titrate slowly; monitor calcium and albumin levels.
Neonates and children: initial 0.25 mcg orally once daily; may increase by 0.25 mcg at 2-4 week intervals as needed; maximum 2 mcg/day.
For hypocalcemia: 0.05-0.1 mcg/kg/day PO, titrated in 0.05 mcg/kg increments every 2-4 weeks; not recommended for IV use in neonates.
Start at low end of dosing range (0.25 mcg once daily) due to possible decreased renal function; monitor serum calcium and phosphorus closely.
Start at the lowest adult dose (0.25 mcg PO daily); increase cautiously due to reduced renal function; monitor serum calcium and renal function frequently.
None officially designated by FDA. However, excessive administration may lead to hypercalcemia, hypercalciuria, and hyperphosphatemia, with risk of soft tissue calcification and renal toxicity.
None
Hypercalcemia risk: avoid excessive dosing; monitor serum calcium, phosphate, and alkaline phosphatase regularly,Hypercalciuria: may cause nephrolithiasis; maintain adequate hydration,Digitalis toxicity: hypercalcemia increases risk; monitor cardiac status,Adynamic bone disease: excessive suppression of PTH in dialysis patients may lead to low bone turnover,Aluminum intoxication: concurrent use of aluminum-containing phosphate binders may increase toxicity
Hypercalcemia,Hypercalciuria,Renal impairment,Monitoring of serum calcium and phosphorus required
Hypercalcemia or evidence of vitamin D toxicity,Hypersensitivity to calcitriol or any component of the formulation,Hyperphosphatemia (unless adequately managed)
Hypercalcemia,Vitamin D toxicity,Malabsorption syndrome,Severe renal impairment
High dietary calcium intake may increase risk of hypercalcemia; advise consistent calcium intake per healthcare provider. No specific restrictions with other foods.
Avoid high-calcium foods or supplements unless directed. Vitamin D analogs may alter calcium absorption. No specific food restriction.
Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcemia) during pregnancy can lead to fetal hypercalcemia, aortic stenosis, retinopathy, and intellectual disability. First trimester: No clear teratogenicity at normal doses. Second and third trimesters: Maternal hypercalcemia from overdosage may cause fetal hypercalcemia and adverse effects. Avoid doses causing maternal serum calcium >11 mg/d L.
FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramnios, and pulmonary hypertension. Avoid use after 20 weeks gestation.
Calcitriol is present in breast milk in low concentrations. The M/P ratio is approximately 0.3–0.4. At maternal therapeutic doses, risk to the infant is minimal. Monitor infant serum calcium if maternal high doses are used.
Excreted in breast milk; M/P ratio unknown. Potential for adverse vascular effects in infants. Contraindicated in breastfeeding due to risk of ductus arteriosus constriction.
Pregnancy may increase vitamin D metabolism; however, calcitriol dose adjustments are generally not required for normal pregnancies. In cases of maternal hypoparathyroidism or renal disease, dosing may need adjustment based on serum calcium levels, as increased maternal blood volume and renal clearance may decrease calcitriol levels. Titrate to maintain normocalcemia.
No standard dose adjustment. Use lowest effective dose for shortest duration. Contraindicated after 20 weeks gestation; avoid in first trimester if possible due to teratogenic potential.
Monitor serum calcium and phosphate levels regularly; hypercalcemia risk especially with thiazide diuretics or high calcium intake. Calcitriol has a rapid onset (hours) and short half-life, making it ideal for acute management of hypocalcemia. Avoid concurrent use of magnesium-containing antacids due to risk of hypermagnesemia.
Calderol (calcifediol) is a vitamin D analog used for renal osteodystrophy. Monitor serum calcium and phosphate levels; do not use with severe hypercalcemia or vitamin D toxicity. Dose adjustment needed in dialysis patients.
Take exactly as prescribed, usually once daily with or without food.,Do not take additional calcium or vitamin D supplements without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, muscle weakness, confusion, or irregular heartbeat.,Avoid excessive intake of calcium-rich foods (e.g., dairy products) unless advised.,Store at room temperature away from light and moisture.
Take exactly as prescribed; do not take extra doses.,Avoid calcium supplements and antacids without consulting your doctor.,Report symptoms of hypercalcemia: nausea, vomiting, constipation, weakness, confusion.,Not for use in children.,Store at room temperature away from light and moisture.
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
"Calcitriol, the active form of vitamin D, may reduce the serum concentration of aripiprazole through a proposed mechanism involving induction of cytochrome P450 (CYP) 3A4 and/or P-glycoprotein (P-gp) efflux transporter. This interaction could lead to decreased systemic exposure of aripiprazole, potentially compromising its antipsychotic efficacy. Clinically, patients may experience worsening of psychotic symptoms or require dose adjustments of aripiprazole when coadministered with calcitriol."
"Calcitriol, the active form of vitamin D, may inhibit the metabolism of delavirdine, a non-nucleoside reverse transcriptase inhibitor (NNRTI), by competing for or downregulating cytochrome P450 (CYP) enzymes, particularly CYP3A4. This can lead to elevated delavirdine plasma concentrations, increasing the risk of dose-related adverse effects such as hepatotoxicity, rash, and central nervous system toxicity. Clinically, patients may experience enhanced delavirdine toxicity without a corresponding increase in antiretroviral efficacy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about CALCITRIOL vs CALDEROL, answered by our medical review team.
CALCITRIOL is a Vitamin D Analog that works by Calcitriol, the active form of vitamin D, binds to vitamin D receptors (VDR) in target tissues, modulating gene transcription. It increases intestinal calcium and phosphate absorption, enhances renal tubular reabsorption of calcium, and promotes bone mineralization by stimulating osteoblast activity.. CALDEROL is a Vitamin D Analog that works by Vitamin D analog; binds to vitamin D receptors, increasing calcium absorption in intestines and promoting bone mineralization.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between CALCITRIOL and CALDEROL depend on the specific clinical indication. These are both Vitamin D Analog agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of CALCITRIOL is: 0.25-0.5 mcg orally once daily, may increase by 0.25 mcg/day at 4-8 week intervals; maximum 2 mcg/day.. The standard adult dose of CALDEROL is: Oral: 0.25-0.5 mcg once daily; titration up to 1 mcg daily based on serum calcium levels. Intravenous: 0.5-2 mcg bolus; maintenance 0.5-2 mcg daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between CALCITRIOL and CALDEROL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. CALCITRIOL is classified as Category A/B. Calcitriol is the active form of vitamin D. At therapeutic doses, no increased risk of major malformations has been consistently demonstrated. However, excessive doses (hypercalcem. CALDEROL is classified as Category C. FDA Pregnancy Category C. First trimester: Potential for cardiac malformations (case reports). Second/third trimester: Risk of premature closure of ductus arteriosus, oligohydramni. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.